| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | CBB-1007 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.6 |
| mRNA | BIBR-1532 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.6 |
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | 0.15 | 0.6 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |